Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The main etiologies of HCC are hepatitis B virus and hepatitis C virus (HCV), and non-hepatitis B/non-hepatitis C HCC (NBNC-HCC) has also been identified as an etiological factor. Although the incidence of HCV-related HCC in Japan has decreased slightly in recent years, that of NBNC-HCC has increased. The onset mechanism of NBNC-HCC, which has various etiologies, remains unclear; however, nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease, is known to be an important risk factor for NBNC-HCC. Among the different advanced glycation end-products (AGEs) formed by the Maillard reaction, glyceraldehyde-derived AGEs, the predominant components of toxic AGEs (TAGE), have been associated with NASH and NBNC-HCC, including NASH-related HCC. Furthermore, the expression of the receptor for AGEs (RAGE) has been correlated with the malignant progression of HCC. Therefore, TAGE induce oxidative stress by binding with RAGE may, in turn, lead to adverse effects, such as fibrosis and malignant transformation, in hepatic stellate cells and tumor cells during NASH or NASH-related HCC progression. The aim of this review was to examine the contribution of the TAGE-RAGE axis in NASH-related HCC.

Key Words: Hepatocellular carcinoma, Nonalcoholic steatohepatitis, Advanced glycation end-products, Toxic advanced glycation end-products, Receptor for advanced glycation end-products, Hepatic stellate cells

Core tip: Expression of the receptor for advanced glycation end-products (RAGE), which is a multi-ligand cell surface receptor, is correlated with the poor therapeutic outcomes and malignancy of hepatocellular carcinoma (HCC). The synthesis of toxic advanced glycation end-products (TAGE), ligands of RAGE, is increased in nonalcoholic steatohepatitis (NASH) as well as in NASH-related HCC. Interactions between TAGE and RAGE induce oxidative stress, which may, in turn, lead to adverse effects in tumor cells and hepatic stellate cells during NASH or NASH-related HCC progression. Therefore, these findings prompted us to suggest that the TAGE-RAGE axis may be a treatment target in NASH-related HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC), which accounts for approximately 90% of all primary liver cancers, is one of the most common malignancies in men and women, and is the third leading cause of cancer-related mortality worldwide[1-3]. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are known to be the main risk factors for HCC, accounting for over 75% of HCC worldwide[4]. The incidence of HCC is particularly high in Asia[3,4], and HBV infection is endemic in eastern/south-eastern Asia, while HCV infection is prevalent in Japan[5-7]. Among diagnosed HCC patients in Japan in 2006-2009, 84.1% had virus-related HCC (HCV: 66.3%, HBV: 14.1%, HCV + HBV: 3.7%) and 15.9% had non-hepatitis B/non-hepatitis C HCC (NBNC-HCC) [alcoholic: 7.2%, etiology unknown: 5.1%, nonalcoholic fatty liver disease (NAFLD): 2.0%, Others: 1.6%][7,8]. Although the incidence of HCV-related HCC has decreased slightly in recent years, that of NBNC-HCC has increased[9,10]. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, has been identified as an important risk factor among the etiological factors of NBNC-HCC. The incidence of NASH-related HCC is expected to increase in the future as the number of patients with NAFLD is increasing worldwide.

Advanced glycation end-products (AGEs) formed by the Maillard reaction, a nonenzymatic reaction between the ketone or aldehyde groups of sugars and the amino groups of proteins, have been implicated in aging and diabetes-related pathological complications[11,12]. This reaction begins with the conversion of reversible Schiff base adducts to more stable covalently bound Amadori rearrangement products. Over the course of days to weeks, these Amadori products undergo further rearrangement reactions to form irreversibly bound moieties known as AGEs[13]. Recent studies have suggested that AGEs are formed not only from sugars, but also from carbonyl compounds produced as a result of the autoxidation of sugars and from other metabolic pathways[14,15]. There is evidence to suggest that glyceraldehyde-derived AGEs (Glycer-AGEs), the predominant components of toxic AGEs (TAGE), are closely associated with insulin resistance, obesity, hypertension, diabetes complications, cardiovascular diseases, dementia, NASH, and cancer[16-24]. We recently demonstrated that TAGE were present at significantly higher concentrations in the sera of patients with NASH than in those with simple steatosis or healthy controls, and that TAGE accumulated in the livers of patients with NASH[25]. Extracellular TAGE induce oxidative stress by binding with the receptor for AGEs (RAGE), which, in turn, causes adverse effects in various types of cells[26-31]. The TAGE-RAGE axis has been shown to increase the malignancy of various types of cancer cells[18,32-35].

These findings suggest that TAGE play an important role in the development and progression of NASH and NASH-related HCC. In this review, we discuss the contribution of the TAGE-RAGE axis in NASH-related HCC.

BACKGROUND OF NASH AND NBNC-HCC

NAFLD, which is the most common liver disease worldwide, is a disease that ranges from simple steatosis to NASH[36-41]. Approximately 20%-30% of the population has evidence of fatty liver disease attributed to NAFLD, and approximately 10% of patients with NAFLD progress to NASH[42]. NASH, which is a disease that has the typical histopathological findings of alcoholic liver disease in patients without a history of significant alcohol abuse, is recognized as a component of the metabolic syndrome and has been closely associated with insulin resistance as well as glucose and lipid metabolic disorders[43-46]. Although simple steatosis appears to be a benign and non-progressive condition, NASH is a potentially progressive disease that can lead to fibrosis, cirrhosis, and HCC[47,48]. Approximately 8%-26% of patients with NASH progress to cirrhosis, and approximately 10% of patients with cirrhotic NASH transform to HCC after 5 years[47,49]. Several case series have recently been published on NASH-related HCC[50,51]. Furthermore, NASH was shown to increase the risk of HCC without the development of cirrhosis[52]. While NASH is a risk factor for HCC, the cirrhosis caused by NASH is also considered to be an important risk factor.

The etiology of NBNC-HCC is often cryptogenic cirrhosis (CC). Most cases of CC are considered to be end-stage NASH because the prevalence of obesity and diabetes among patients with CC is similar to that of patients with NASH[53]. In addition, patients who undergo orthotopic liver transplantation for CC often develop NAFLD and NASH after transplant[54]. However, the histopathological features of NASH often disappear when cirrhosis is established[55]. Marrero et al[56] reported that HCV (51%) and CC (29%) were the first and second most common etiologies among 105 patients with HCC in the United States, respectively, that 50% of patients with CC had a prior histological diagnosis of NASH or clinical features associated with NAFLD, and that NAFLD-related CC accounted for 13% of patients with HCC. These findings suggested the existence of NASH-related HCC.

ALTERNATIVE ROUTES FOR THE FORMATION OF AGES IN VIVO

The formation of AGEs, which occurs through a non-enzymatic glycation reaction, is known to result from not only glucose, but also the actions of various metabolites that are primarily located intracellularly[13,15,57].

We previously reported the contribution of fructose, α-hydroxyaldehydes (glyceraldehyde and glycolaldehyde), and dicarbonyl compounds (methylglyoxal, glyoxal, and 3-deoxyglucosone) as well as glucose in the glycation of proteins. Seven immunochemically distinct classes of AGEs (Glu-AGEs, glucose-derived AGEs; Fru-AGEs, fructose-derived AGEs; Glycer-AGEs, glyceraldehyde-derived AGEs; Glycol-AGEs, glycolaldehyde-derived AGEs; MGO-AGEs, methylglyoxal-derived AGEs; GO-AGEs, glyoxal-derived AGEs; and 3-DG-AGEs, 3-deoxyglucosone-derived AGEs) were detected in the sera of type 2 diabetic subjects undergoing hemodialysis[13,58-61]. These findings suggested that all seven forms of AGEs were synthesized in vivo (Figure 1).

Figure 1 Alternative routes for the formation of advanced glycation end-products in vivo. Reducing sugars, such as glucose, fructose, and glyceraldehyde are known to react non-enzymatically with the amino groups of proteins to form reversible Schiff bases and Amadori product/Heyns products. These early glycation products undergo further complex reactions such as rearrangement, dehydration, and condensation to become irreversibly cross-linked, heterogeneous fluorescent derivatives, termed advanced glycation end-products (AGEs). Glu-AGEs: Glucose-derived AGEs; Fru-AGEs: Fructose-derived AGEs; Glycer-AGEs: Glyceraldehyde-derived AGEs; Glycol-AGEs: Glycolaldehyde-derived AGEs; MGO-AGEs: Methylglyoxal-derived AGEs; GO-AGEs: Glyoxal-derived AGEs; 3-DG-AGEs: 3-deoxyglucosone-derived AGEs; CML: Nε-(carboxymethyl)lysine; P-NH₂: Free amino residue of a protein; AR: Aldose reductase; SDH: Sorbitol dehydrogenase; FK: Fructokinase; HFCS: High-fructose corn syrup; HbA1c: Hemoglobin A1c; TAGE: Toxic advanced glycation end-products.

PATHWAY FOR THE IN VIVO FORMATION OF TAGE

Glyceraldehyde, a precursor of TAGE, is produced by two pathways (the glycolytic pathway and fructose metabolic pathway)[17,21,22,24,62]. In the glycolytic pathway (glycolysis), the intermediate glyceraldehyde-3-phosphate (G-3-P) is metabolized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH), G-3-P accumulates intracellularly due to a decrease in GAPDH enzyme activity. Accumulated G-3-P then shifts to another metabolic route, and the amount of glyceraldehyde is increased. In the fructose metabolic pathway (fructolysis), fructose is mainly metabolized in the liver. Fructose is phosphorylated to fructose-1-phosphate (F-1-P) by a fructokinase, and liver aldolase B cleaves F-1-P to produce dihydroxyacetone phosphate and glyceraldehyde. The accumulated glyceraldehyde due to a metabolic disorder is then transported or leaks passively across the plasma membrane, thereby promoting the intracellular and extracellular formation of TAGE (Figure 2).

Figure 2 In vivo production routes of glycer-advanced glycation end-products (toxic advanced glycation end-products). The chronic and excessive ingestion of sugar-sweetened beverages (HFCS/sucrose) increases the levels of the sugar metabolite, glyceraldehyde in the liver. The glycolytic intermediate glyceraldehyde-3-phosphate (G-3-P) is normally catabolized (glycolysis) by the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). G-3-P accumulates intracellularly with a decline in GAPDH activity. The metabolism of G-3-P then shifts to another route, resulting in an increase in the amount of glyceraldehyde, which promotes the formation of glycer-advanced glycation end-products (AGEs) (TAGE). Fructose from the daily diet and polyol pathway is phosphorylated to fructose-1-phosphate (F-1-P) by fructokinase and is then catabolized to glyceraldehyde and dihydroxyacetone phosphate by aldolase B (fructolysis). The newly synthesized glyceraldehyde is then transported or leaks passively across the plasma membrane. Glyceraldehyde promotes the formation of TAGE both intracellularly and extracellularly. DHA-P: Dihydroxyacetone-phosphate; FK: Fructokinase; HFCS: High-fructose corn syrup; TAGE: Toxic advanced glycation end-products; TG: Triglyceride; Protein-NH2: Free amino residue of a protein.

SERUM TAGE LEVELS IN NASH AND NBNC-HCC

AGEs were originally characterized by their ability to form cross-links with and between amino groups and have a yellow brown fluorescent color. However, this term is now used for a broad range of advanced products of the glycation process, including Nε-(carboxymethyl)lysine (CML), Nε-(carboxyethyl)lysine, and pyrraline, which are not cross-linked proteins and do not have color or fluorescence[13,63-67]. CML was previously shown to be formed from precursors such as glycolaldehyde and glyoxal via the intra-molecular Cannizzaro reaction, a process that is largely independent of glucose autoxidation[14]. CML may also be formed independently of the presence of fructose-lysine during the metal-catalyzed oxidation of low-density lipoproteins and peroxidation of polyunsaturated fatty acids[68]. A recently supported concept is that CML is a marker of oxidation rather than glycation.

Sebeková et al[69] initially suggested that the catabolism and clearance of circulating CML was impaired by various liver diseases. In their study, plasma CML levels were measured in 51 patients with liver cirrhosis (five of whom were followed for 36 mo after liver transplantation) and 19 healthy controls. The main findings obtained were that: (1) plasma CML levels were markedly elevated in patients with liver cirrhosis and positively correlated with severity of the disease; (2) plasma CML levels were inversely associated with residual liver function in patients, as estimated by serum albumin and plasma bilirubin levels; and (3) plasma CML levels were markedly decreased (to approximately 50% of those before treatment) within 3 mo of liver transplantation. These findings suggested that the liver may play an important role in the removal of circulating CML and that the hepatic clearance of circulating CML may be impaired due to liver cirrhosis. Yagmur et al[70] also reported that serum CML levels were significantly higher in patients with liver cirrhosis than in patients without cirrhosis, and were positively associated with the severity of cirrhosis defined by the Child-Pugh score. These findings suggested that circulating CML levels may be a useful biomarker for evaluating residual liver function. However, Moy et al[71] recently reported that serum CML levels were inversely correlated with the risk of HCC. They measured serum CML levels in 145 patients with HCC and 340 control patients, who were male Finnish smokers, and found that high serum CML levels correlated with a lower risk of HCC. Furthermore, this relationship did not change in the case of NBNC-HCC. Therefore, the relationship between circulating CML levels and liver disease needs to be examined in more detail in future studies.

Our clinical data indicated that TAGE played a role in the etiology of NASH and that serum TAGE levels were a useful clinical tool for discriminating between NASH-related HCC, NASH, and simple steatosis[25,72,73]. We measured serum AGE levels (CML, Glu-AGEs, and TAGE) in 66 NASH patients without cirrhosis, 10 patients with simple steatosis, and 30 control patients. We found that serum TAGE levels were significantly higher in NASH patients than in those with simple steatosis and the controls; however, no significant difference was observed in CML and Glu-AGE levels between the groups[25]. We measured serum TAGE levels in 43 NASH patients with dyslipidemia in order to determine whether they played a role in the treatment of NASH. Serum TAGE levels were measured and clinical laboratory tests were performed periodically during the administration of atorvastatin (10 mg daily), a hydroxymethylglutaryl-CoA reductase inhibitor, for 12 mo. This treatment significantly decreased serum TAGE levels, and significantly improved biochemical and histological findings[72]. We also measured serum TAGE levels in 90 patients with NBNC-HCC, 56 NASH patients without HCC, and 27 control patients, and found that serum TAGE levels were significantly higher in NBNC-HCC patients than in those with NASH without HCC and controls. Among the patients with NBNC-HCC, 10 had NASH-related HCC, 49 alcoholic-related HCC, and 31 etiology unknown HCC, and no significant differences were observed in serum TAGE levels between these groups[73]. These findings suggested that the formation of TAGE, but not CML, was enhanced by the development and progression of NASH, and that enhanced TAGE may influence the development and progression of NBNC-HCC. Brenner et al[74] previously reported that increases in AGE-RAGE-mediated inflammation in patients with end-stage liver diseases including HCC following liver transplantation were dependent on reactive carbonyl species-derived AGEs, but not CML. Therefore, TAGE may play a more important role in the development and progression of NASH-related HCC than CML[24,75].

RAGE EXPRESSION IN HCC

RAGE, a multi-ligand cell surface receptor, interacts with distinct molecules that have been implicated in homeostasis, development, and inflammation. RAGE binding by ligands such as AGEs, high mobility group box 1, and S100/calgranulins has been shown to trigger the activation of key cell signaling pathways, thereby reprogramming cellular properties[76]. Previous studies suggested that the expression of RAGE was associated with the malignant progression of cancer [77-80].

In the liver, RAGE is expressed in hepatocytes and hepatic stellate cells (HSCs)[81,82]. Liver damage caused by various factors such as inflammation, drugs, and hepatic ischemia/reperfusion (I/R) is known to increase the expression of RAGE, which induces further liver failure[83-89]. For example, Kuhla et al[89] reported that exposure to galactosamine/lipopolysaccharides induced RAGE expression, leading to inflammation, and a pre- or post-treatment with an anti-RAGE antibody attenuated enhanced inflammation, apoptosis, and necrosis. Therefore, RAGE is crucially involved in the exacerbation of liver disease and may also play a role in HCC, which occurs following liver failure. A previous study reported that the expression of RAGE mRNA was higher in the liver cells of hepatitis and HCC patients than in normal liver cells[81], and RAGE expression correlated with the poor therapeutic outcomes and malignancy of HCC[90,91]. Ito et al[90] investigated the relationship between RAGE expression and clinical outcomes in 65 patients who underwent initial hepatectomy for HCC. The number of patients that expressed RAGE was significantly higher among those with well and poorly differentiated HCC than those with moderately differentiated HCC, and the 5-year survival rate was significantly lower in the RAGE-positive group than in the RAGE-negative group. Yang et al[91] investigated the relationship between RAGE expression and clinicopathological features in 75 patients with HCC. HCC tissues expressed significantly higher levels of RAGE than non-cancerous tissues, and the expression of RAGE was closely associated with pathological staging and lymph-vascular space invasion. Furthermore, recent studies suggested that RAGE expression increased under hypoxic conditions in HCC cell lines[79,81]. The survival of RAGE-transfected cells was significantly prolonged under hypoxic conditions, and an anti-RAGE siRNA treatment eliminated this influence[81]. Therefore, inhibitors of RAGE expression may be effective as new HCC therapeutic drugs. Koh et al[88] reported that losartan, a peroxisome proliferator-activated receptor-γ (PPAR-γ) activator, attenuated the enhanced expression of RAGE in I/R and attenuated liver damage-inducing factors such as aspartate or alanine aminotransferase, tumor necrosis factor-α, and interleukin-6. Yang et al[91] demonstrated that pioglitazone, a PPAR-γ agonist, decreased the expression of RAGE in HCC cell lines, suppressed cell proliferation and cell invasion, and induced apoptosis and cell cycle arrest. We also previously reported that telmisartan may down-regulate the expression of RAGE through its PPAR-γ-modulating activity in the human HCC cell line, Hep3B. Telmisartan, but not candesartan, decreased RAGE mRNA and protein expression levels, and GW9662, an inhibitor of PPAR-γ, blocked the inhibitory effects of telmisartan on RAGE mRNA and protein expression. Troglitazone and ciglitazone, which are full agonists of PPAR-γ, mimicked the effects of telmisartan[92]. Therefore, PPAR-γ activators may become important targets as inhibitors of RAGE expression in treatment strategies for HCC.

Full-length RAGE, which is generally referred to as RAGE, induces adverse effects, whereas the soluble form of RAGE (sRAGE) attenuates these effects. sRAGE, a circulating isoform of RAGE, has been detected in plasma and consists of an endogenous secretory RAGE (esRAGE), which is a splice variant, as well as a proteolytically cleaved isoform of cell surface RAGE. sRAGE, including esRAGE, is known to act as a decoy receptor of RAGE by binding with AGEs and other ligands competitively[93,94]. Zeng et al[83] reported that the survival of mice treated with sRAGE after hepatic I/R injury was better than that of mice treated with PBS, and that the blockade of RAGE signaling by sRAGE attenuated hepatic I/R injury. In order to elucidate the relationship between serum sRAGE levels and NASH, Yilmaz et al[95] measured serum sRAGE levels in 48 patients with NASH (definite NASH, n = 40, and borderline NASH, n = 8) and 14 control patients, and found that serum sRAGE levels were significantly lower in patients with NASH than in controls. Furthermore, regarding the relationship between serum sRAGE levels and HCC, Moy et al[71] reported that serum sRAGE levels inversely correlated with the risk of HCC or NBNC-HCC, in addition to serum CML levels, as discussed above. Kohles et al[96] also recently demonstrated that serum sRAGE levels were significantly lower in patients with progressive HCC than in patients without progressive HCC. On the other hand, we, along with others, recently found that serum sRAGE levels were positively, rather than inversely, associated with serum TAGE levels in non-diabetic and diabetic subjects[97,98]. These findings suggested that since TAGE up-regulates the expression of RAGE, increases in sRAGE levels may reflect the expression of full-length RAGE[99]. However, the relationship between sRAGE and TAGE in NASH or NASH-related HCC has not yet been elucidated in detail; therefore, further analyses will be necessary in the future.

THE TAGE-RAGE AXIS IN HCC AND HSCS

We previously described the effects of the TAGE-RAGE axis in HCC[100]. TAGE induced the expression of C-reactive protein (CRP), an inflammatory marker, via the activation of Rac-1 in Hep3B, and its induction was attenuated by a pretreatment with anti-RAGE anti-serum. Signal transducer and activator of transcription 3 - and nuclear factor-kappa B-dependent pathways and a reactive oxygen species (ROS)-dependent pathway exist in this signaling pathway, and have been suggested to participate with each other in the early and late stages of CRP induction[100]. A previous study reported a relationship between increases in the expression of CRP and the malignancy of HCC. Kinoshita et al[101] analyzed the relationship between serum CRP levels and poor prognoses in 186 patients with HCC, and demonstrated that serum CRP levels correlated with a poor prognosis in HCC patients. Furthermore, Kim et al[102] examined serum CRP levels in 83 HCC patients with malignant portal vein invasion and 1056 HCC patients without portal vein invasion who underwent liver resection. They found that CRP levels were significantly higher in HCC patients with malignant portal vein invasion than in HCC patients without portal vein invasion, and that CRP levels correlated with the risk of tumor recurrence in HCC patients with malignant portal vein invasion. TAGE significantly enhanced cell proliferation in the human HCC cell line HuH7, which expressed RAGE on the cell surface, but not in the human HCC cell line HepG2, which does not express RAGE. Flow cytometry with anti-RAGE antibody staining demonstrated the expression of membrane-bound RAGE in both HuH7 and HepG2 cells at 24.3% and 6.2%, respectively. Furthermore, MK615, an extract of the Japanese apricot, was shown to suppress TAGE-induced cell proliferation by decreasing the expression of RAGE on the cell surface[34]. The expression of vascular endothelial growth factor mRNA and protein was significantly greater in Hep3B cells treated with TAGE than with the control non-glycated bovine serum albumin (BSA). Furthermore, the proliferation and migration of as well as tube formation by human umbilical vein endothelial cells was significantly greater with the conditioned medium of TAGE-treated Hep3B cells than with the conditioned medium of control non-glycated BSA-treated Hep3B cells. On the other hand, TAGE did not influence HepG2 cells[34]. This may have been due to differences in the expression of RAGE on cell surfaces. Glu-AGEs were also found to have no influence on Hep3B or HepG2 cells because they are known to have lower binding affinity with RAGE than TAGE. The findings suggested that the TAGE-RAGE axis played an important role in the malignant transformation of HCC (Figure 3).

Figure 3 Proposed model for the contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. The interaction between TAGE and RAGE alters intracellular signaling in tumor cells and hepatic stellate cells, and induces angiogenesis, invasion, migration, proliferation, and fibrosis. This cooperation by the TAGE-RAGE axis may lead to the malignant progression of nonalcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC). CML and sRAGE inversely correlate with the risk of HCC, and sRAGE, which plays the role of a decoy receptor of RAGE, prevents the malignant progression of HCC. The TAGE-RAGE axis may become a treatment target in NASH and NASH-related HCC. CML: Nε-(carboxymethyl)lysine; ECs: Endothelial cells; EMT: Epithelial mesenchymal transition; HSCs: Hepatic stellate cells; MCP-1: Monocyte chemoattractant protein-1; RAGE: Receptor for advanced glycation end-products; sRAGE: Soluble receptor for advanced glycation end; TAGE: Toxic advanced glycation end-products; TGF-β1: Transforming growth factor-β1; VEGF: Vascular endothelial growth factor.

We previously reported the effects of the TAGE-RAGE axis in HSCs. TAGE induced the expression of transforming growth factor-β1 and collagen type Iα2, which are fibrogenic factors, as well as that of monocyte chemoattractant protein-1, an inflammatory factor, via the generation of NADPH oxidase-derived ROS in the human stellate cell line LI90[103]. The activation of HSCs, which mainly produce the extracellular matrix, has been shown to play a pivotal role in liver fibrogenesis[104], and promotes the onset and progression of HCC[105,106]. Amann et al[107] found that activated HSCs increased the malignancy of HCC. The main findings of their study were: (1) the conditioned medium of activated HSCs significantly increased the proliferation and migration of human HCC cell lines (HepG2, Hep3B, and PLC); (2) activated HSCs significantly increased the volumes of spheroids formed in the three-dimensional coculture of HSCs and HCC, and these spheroids showed smaller central necrotic areas than those of spheroids formed only with HCC; and (3) tumor size and invasion ability were significantly greater following the co-implantation of HSCs and HepG2 into nude mice than the implantation of HepG2 alone in vivo. Furthermore, Yang et al[108] reported that collagen type I, which is secreted by HSCs, enhanced the metastatic ability of HCC via epithelial mesenchymal transition. These findings suggested that the TAGE-RAGE axis in HSCs indirectly caused the malignant transformation of HCC (Figure 3).

CONCLUSION

Slight increases in the incidence of NBNC-HCC in recent years have changed the etiology of HCC. The onset mechanism of NBNC-HCC, the etiology of which is varied, currently remains unclear, and, as a consequence, has led to its later diagnosis and larger NBNC-HCC tumors than virus-related HCC tumors. However, the survival rate of early stage NBNC-HCC patients was previously reported to be higher than that of virus-related HCC patients[109-111]. The clinical data suggest that NBNC-HCC can be resolved by early pathogenesis-based treatment, because most of patients diagnosed with NBNC-HCC may have NASH, an important etiological factor of NBNC-HCC. We herein indicated that TAGE, enhanced by NASH, contributes to the malignancy of NASH-related HCC via RAGE. Therefore, the TAGE-RAGE axis may become an important treatment target in NASH-related HCC, and warrants further study.